Pronestyl

(procainamide)

ApprovedSmall molecule

Bristol-Myers Squibb

Pronestyl is one of 81 small molecule programs targeting Cardiac Arrhythmia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrhythmiaActive, not recruiting

Cardiac ArrestActive, not recruiting

Atrial FibrillationActive, not recruiting

Cardiac ArrhythmiaApproved

Active, not recruiting

Cardiac ArrestPhase 3

Active, not recruiting

Atrial FibrillationPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Pronestyl

Bristol-Myers Squibb

Approved

2 2

Calquence

AstraZeneca

Preclinical

1 3

Calan

VVal Adams

Preclinical

4 4

Brukinsa

BBeOne Medicines

Preclinical

1 5

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 7

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Direct Anticoagulant

Bayer

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiac Arrhythmia2 trials

Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias

Completed·HHospital Clinic of Barcelona·Phase 4·NCT00702117·123 enrolled

Prevention of Post-Operative Cardiac Arrhythmias

Unknown status·JJeffrey Moak·Phase 4·NCT04234906·870 enrolled

Atrial Fibrillation2 trials

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000556

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

Completed·OOttawa Hospital Research Institute·Phase 4·NCT04485195·350 enrolled

Cardiac Arrest1 trial

Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)

Completed·UUniversity of Washington·Phase 3·NCT00000464

Drug Therapy1 trial

Acute Mechanical Response to Anti-arrhythmic Drug Therapy

Withdrawn·—·N/A·NCT02575534

CAR1 trial

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)

Completed·UUniversity of Utah·Phase 3·NCT00000518

1 more indication

Unspecified1 trial

ST-segment Elevation as an AF Endophenotype

Completed·VVanderbilt University Medical Center·N/A·NCT01205529·161 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

PRONESTYL

NDA NDA007335

Jan 1, 1982

PRONESTYL

NDA NDA017371

Jan 31, 1996

PROCANBID

NDA NDA020545

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for procainamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — procainamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for procainamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020545). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Pronestyl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiac Arrhythmia2 trials

Atrial Fibrillation2 trials

Cardiac Arrest1 trial

Drug Therapy1 trial

CAR1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News